Skip to main content

Generative AI

Alnylam Pharmaceuticals adopts Amazon Q Business and accelerates enterprise-wide AI adoption

Alnylam leverages Amazon Q Business to optimize data resource access and fast-track innovation efforts
Missing alt text value
Alnylam has led the translation of RNA interference (RNAi) from Nobel Prize–winning discovery into an entirely new class of medicines, which has the potential to help people all over the world to live longer, healthier, and fuller lives.
Amazon Q has the potential to expedite and scale our generative AI initiatives across the entire company. By providing a unified platform to access our data sources, Amazon Q has the power to significantly accelerate our delivery cycles. Amazon Q will empower our teams to swiftly roll out new AI applications, broadening possibilities for exploring diverse use cases and delivering cutting-edge business capabilities. With ACL-aware enterprise connectors and preconfigured RAG orchestration, Amazon Q has the promise to cut through typical impediments that bog down AI projects and technical complexities. This will take our AI initiatives to the next level, ushering rapid innovation and improving business operations.

Murtaza Cherawala

Senior Director of Data Management and AI, Alnylam

Alnylam Transforms Product Complaint Management with Amazon Q Business and Amazon Bedrock

Learn how Alnylam Pharmaceuticals uses generative AI to enhance employee productivity and streamline product complaint management.

Read more
Rows of glass vials on a production line in a pharmaceutical manufacturing facility.

Did you find what you were looking for today?

Let us know so we can improve the quality of the content on our pages